Chemistry:Conveglipron

From HandWiki

Conveglipron (INN; developmental code name HDM1002) is a glucagon-like peptide-1 (GLP-1) receptor agonist which is under development for the treatment of type 2 diabetes, obesity, and diabetes mellitus.[1][2][3][4][5] It is taken orally.[1][3] The drug is a small molecule and is a selective and highly potent full agonist of the GLP-1 receptor with antihyperglycemic and antiobesity effects in animals.[5] Conveglipron is under development by Huadong Medicine in China.[1][2][3] As of January 2026, it is in phase 3 clinical trials for type 2 diabetes, phase 2 trials for obesity, and phase 1 trials for diabetes mellitus.[1][2][3]

References

  1. ↑ 1.0 1.1 1.2 1.3 "HDM 1002". AdisInsight. Springer Nature Switzerland AG. 14 January 2026. https://adisinsight.springer.com/drugs/800078896. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Conveglipron with Synapse". 11 February 2026. https://synapse.patsnap.com/drug/e787d48e59264ff588799134f588ac6d. 
  3. ↑ 3.0 3.1 3.2 3.3 "Conveglipron". OZMOSI. https://pryzm.ozmosi.com/product/30449. 
  4. ↑ "First-in-human study of HDM1002, a GLP-1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers". Diabetes, Obesity & Metabolism 27 (10): 5622–5631. October 2025. doi:10.1111/dom.16610. PMID 40662378. 
  5. ↑ 5.0 5.1 "59th EASD Annual Meeting of the European Association for the Study of Diabetes: Hamburg, Germany, 2 - 6 October 2023: Discovery of HDM1002, a selective, potent, oral small-molecule GLP-1R agonist for treatment of type 2 diabetes and obesity". Diabetologia 66 (Suppl 1): S1–S536 (S316). 2023. doi:10.1007/s00125-023-05969-6. ISSN 0012-186X. https://link.springer.com/10.1007/s00125-023-05969-6. Retrieved 18 February 2026. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Conveglipron&oldid=4308580"